Emergence of bedaquiline resistance in a high tuberculosis burden country. Issue 3 (24th March 2022)

• Record Type: Journal Article
• Authors: Chesov, Elena; Chesov, Dumitru; Maurer, Florian P.; Andres, Sönke; Utpatel, Christian; Barilar, Ivan; Donica, Ana; Reimann, Maja; Niemann, Stefan; Lange, Christoph; Crudu, Valeriu; Heyckendorf, Jan; Merker, Matthias
• Is Part Of: European respiratory journal. Volume 59:Issue 3(2022)
• Publication Date: 2022-03-24
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00621-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

Rationale: Bedaquiline has been classified as a group A drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) by the World Health Organization; however, globally emerging resistance threatens the effectivity of novel MDR-TB treatment regimens. Objectives: We analysed pre-existing and emerging bedaquiline resistance in bedaquiline-based MDR-TB therapies, and risk factors associated with treatment failure and death. Methods: In a cross-sectional cohort study, we employed patient data, whole-genome sequencing (WGS) and phenotyping of Mycobacterium tuberculosis complex (MTBC) isolates. We could retrieve baseline isolates from 30.5% (62 out of 203) of all MDR-TB patients who received bedaquiline between 2016 and 2018 in the Republic of Moldova. This includes 26 patients for whom we could also retrieve a follow-up isolate. Measurements and main results: At baseline, all MTBC isolates were susceptible to bedaquiline. Among 26 patients with available baseline and follow-up isolates, four (15.3%) patients harboured strains which acquired bedaquiline resistance under therapy, while one (3.8%) patient was re-infected with a second bedaquiline-resistant strain. Treatment failure and death were associated with cavitary disease (p=0.011), and any additional drug prescribed in the bedaquiline-containing regimen with WGS-predicted resistance at baseline (OR 1.92 per unit increase, 95% CI 1.15–3.21; p=0.012). Conclusions: MDR-TB treatments based on bedaquiline require a functional background regimen to achieve high cure rates and to prevent the evolution of bedaquiline resistance. Novel MDR-TB therapies with bedaquiline require timely and comprehensive drug resistance monitoring. Bedaquiline resistance emerged in >15% of Mycobacterium tuberculosis complex strains obtained from follow-up isolates of MDR-TB patients. Insufficient backbone regimens and cavitary disease were associated with treatment failure and death. https://bit.ly/2UHoVyG